Everolimus and bevacizumab are two drugs already approved for treating advanced renal cell carcinoma, a serious form of kidney cancer. In this study, researchers are evaluating the safety and effectiveness of using both drugs together in patients with advanced non-clear cell renal cell cancer. The hope is that both drugs together may be more effective than either drug alone.
Everolimus is an oral drug that inhibits a molecule called mTOR, which helps cancer cells grow. Bevacizumab inhibits the formation of blood vessels that tumors need to grow and spread. It is given intravenously (by vein).